Literature DB >> 2454315

Adult rheumatoid arthritis is associated with MC1, a new HLA-D encoded determinant.

A B Carpenter1, L E Kahl, C D Bartkowiak, R J Duquesnoy, C H Eisenbeis.   

Abstract

We evaluated the association of a new HLA-D encoded determinant, MC1, with adult rheumatoid arthritis (RA). This determinant associates with DR1 and DR4 and can be defined by serological typing. We found MC1 in 83% of 80 patients with RA vs 43% of controls. Although the frequencies of DR1 and DR4 were both significantly increased in patients with RA compared with controls, MC1 had the highest relative risk (6.2) of any HLA-DR antigen tested. MC1 negative and positive populations were not significantly different in any of a variety of clinical and laboratory variables including age, sex, disease duration, age at onset, hours of morning stiffness, functional class, joint count, presence of subcutaneous nodules or bony erosions, frequency of side effects to gold or D-penicillamine, sedimentation rate, and antinuclear antibody.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454315

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

1.  Diversity of anti-HLA-DR antibodies elicited by distinct anti-idiotypic monoclonal antibodies recognizing idiotopes co-expressed by the immunizing monoclonal antibody.

Authors:  S M Mariani; E A Armandola; S Ferrone
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

2.  HLA-DR1 and DRw6 association in DR4-negative rheumatoid arthritis patients.

Authors:  B Lang; I Melchers; A Urlacher; R F Tanzi-Fetta; S Kohlbrenner; M M Tongio; H H Peter
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

3.  HLA and rheumatic fever in Turkish Children.

Authors:  H E Khosroshahi; O Kahramanyol; L Doğanci
Journal:  Pediatr Cardiol       Date:  1992-10       Impact factor: 1.655

Review 4.  Molecular basis of human leukocyte antigen class II disease associations.

Authors:  D Charron
Journal:  Adv Immunol       Date:  1990       Impact factor: 3.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.